Today’s Research Reports on Covalon Technologies Ltd., DiaMedica Therapeutics Inc., Emerald Health Therapeutics, Inc. and Sernova Corp.

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Covalon Technologies Ltd.
https://ub.rdinvesting.com/news/?ticker=COV.V

DiaMedica Therapeutics Inc.
https://rdinvesting.com/news/?ticker=DMA.V

Emerald Health Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=EMH.V

Sernova Corp.
https://rdinvesting.com/news/?ticker=SVA.V

Covalon Technologies’ stock moved 6.24% lower Tuesday, to close the day at $5.11. The stock recorded a trading volume of 32,131 shares, which was below its three months average volume of 33,306 shares. In the last year, Covalon Technologies’ shares have traded in a range of 1.62 – 8.00. The share price has gained 215.43% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $5.92 is greater than its 200-day moving average of $4.52. Shares of Covalon Technologies are trading at a Price to Earnings ratio of 63.09. Shares of Covalon Technologies have gained approximately 4.5 percent year-to-date.

Access RDI’s Covalon Technologies Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=COV.V

On Tuesday, shares of DiaMedica Therapeutics recorded a trading volume of 115,900 shares, which was below the three months average volume of 151,436 shares. The stock ended the day flat at 0.37. The share price has gained 76.19% from its 52 week low with a 52 week trading range of 0.21 – 0.43.The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.31 is below its 200-day moving average of $0.33. Shares of DiaMedica Therapeutics have gained approximately 27.59 percent year-to-date.

Access RDI’s DiaMedica Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=DMA.V

Emerald Health Therapeutics’ stock edged 0.67% lower Tuesday, to close the day at $5.90. The stock recorded a trading volume of 2,279,695 shares, which was above its three months average volume of 2,206,873 shares. In the last year, Emerald Health Therapeutics’ shares have traded in a range of 1.03 – 25.06. The share price has gained 472.82% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $6.59 is greater than its 200-day moving average of $3.61. Shares of Emerald Health Therapeutics, Inc. have gained approximately 13.24 percent year-to-date.

Access RDI’s Emerald Health Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EMH.V

On Tuesday, shares of Sernova recorded a trading volume of 171,550 shares, which was below the three months average volume of 285,210 shares. The stock ended the day 2.50% lower at 0.39. The share price has gained 178.57% from its 52-week low with a 52-week trading range of 0.14 – 0.51.The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.41 is greater than its 200-day moving average of $0.30. Shares of Sernova have fallen approximately 7.14 percent year-to-date.

Access RDI’s Sernova Corp. Research Report at:
https://rdinvesting.com/news/?ticker=SVA.V

Our Actionable Research on Covalon Technologies Ltd. (TSXV:COV.V), DiaMedica Therapeutics Inc. (TSXV:DMA.V), Emerald Health Therapeutics, Inc. (TSXV:EMH.V) and Sernova Corp. (TSXV:SVA.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 492076